
Conference Coverage
Latest Content

Shorts










Podcasts
Videos
All News

FDA grants Priority Review for Padcev plus Keytruda in muscle-invasive bladder cancer, showing improved survival and reduced recurrence risk.

A man with small cell lung cancer describes carboplatin-related hearing loss, fatigue and daily challenges that have reshaped his life, while holding onto perspective and resilience.

At NCCN 2026, Anjali Albanese discussed how young adults with cancer face grief, isolation and loss of control that impact their emotional well-being.

Gotistobart improved responses and survival versus docetaxel in pretreated squamous NSCLC, offering a potential chemo-free option with durable benefit in some patients.

Dr. Michael K. Wong explains why immunotherapy makes skin hypersensitive, and how to spot red-flag reactions during melanoma care.

Learn about breast angiosarcoma, a rare blood vessel cancer. Discover the signs of primary and secondary cases to help guide your oncology discussion.

Dr. Charles Peyton discusses the growing number of bladder cancer therapies and emphasizes the importance of personalized care and patient education.

Dr. Thomas Flaig highlights the importance of multidisciplinary care and clinical trials in guiding personalized bladder cancer treatment decisions.

Dr. Michael Wong shares "sun smart" tips for melanoma survivors, debunking tanning myths and highlighting why clothing is better than sunscreen alone.

Moving into a new home often means sorting through years of belongings. Sometimes, hidden in a box, we uncover pieces of the past that force us to confront what we’ve endured.

The latest episode of the "Breast Cancer Briefing" podcast highlights the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

Study finds how multiple myeloma cells adapt to immunotherapy, helping explain why patients relapse and guiding personalized treatment approaches.

The NexTGen team launches the world's largest CAR-T cell trial for pediatric solid tumors, offering new hope for children with relapsed cancer.

Darlifarnib plus Cabometyx showed tumor responses in resistant kidney cancer following prior treatment.

An expert discusses the need to tailor treatment duration in bladder cancer, balancing improved outcomes with toxicity and exploring new tools.























